• Vaxil Locations
  • Contact Us
  • Subscribe
Vaxil Bio
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media

Investor Presentations

To download, please click below.

 

executive summary

exec-one-pager

Vaxil Overview – Executive Summary

AACR 2017 Poster – Immucin Acts as Novel Neoantigen

Vaxil AACR Poster - Immucin Acts as Novel Neoantigen

Vaxil – AACR Poster – Immucin Acts as True Neoantigen

Cancer & Multiple Myeloma

Cancer is the leading cause of death worldwide, accounting for 8,000,000 deaths per annum and 12,000,000 new cases. Multiple Myeloma (MM) is the second-most common blood cancer, in which plasma cells accumulate in bone marrow leading to bone destruction and marrow failure. MM accounts for 1% of all cancers and is still considered incurable given the vast majority of patients eventually relapse. A better approach is desperately needed.

Vaxil™ was founded by Weizmann Institute scientists, Israel's top research university, in order to provide an altogether novel approach to immunotherapy. Vaxil™ has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals.

The whole story

  • Prior Immunotherapy Deals

Vaxil Canada
First Canadian Place, 34th Floor, 100 King Street W., Toronto, Ontario. M2N 6N4 Canada

Vaxil Israel
3 Pinhas Sapir Street, 3rd Floor, Weizmann Science Park, 74140, Rehovot, Israel

Corporate

  • Home
  • About Vaxil
  • Vaxil Locations
  • Contact Us
  • Board & Executives
  • News and Updates

INVESTORS

  • Investor Presentations
  • Public Filings
  • News and Updates
  • In the Media
  • Video
  • Scientific Publications
Copyright 2025 © VAXIL BIO THERAPEUTICS | Vaxil Bio therapeutics is an Israeli biotech focused on cancer immunotherapy, based in the Weizmann Science Park in Rehovot, Israel. Vaxil is listed on the TSX-Venture as VXL
  • About Vaxil
  • TEAM
  • INTELLECTUAL PROPERTY
  • News and Updates
  • In the Media
  • Vaxil Locations
  • Contact Us
  • Subscribe